Also remember that the clinical data was not that great for MSB and they managed to get them over the line with the panel decision 8-2.
the above panel decision is not binding and they need to wait until late September to see if they actually get approved.
At at least we have very high WOMAC scores but I would very much like to see the expert FDA read out to see what their thoughts were. This will be very interesting
and is what we need to look for!
Also remember that the clinical data was not that great for MSB...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 25.0¢ | $70.91K | 279.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 75357 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 116338 | 2 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.000 ( 0.16 %) |
||||
| Open | High | Low | Volume | ||
| 25.5¢ | 26.0¢ | 25.0¢ | 98848 | ||
| Last updated 15.58pm 04/06/2024 ? | |||||
| PAR (ASX) Chart |